Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr 17:10:109.
doi: 10.3389/fnagi.2018.00109. eCollection 2018.

Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease

Affiliations
Review

Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease

Xian-Si Zeng et al. Front Aging Neurosci. .

Abstract

It has been 200 years since Parkinson disease (PD) was described by Dr. Parkinson in 1817. The disease is the second most common neurodegenerative disease characterized by a progressive loss of dopaminergic neurons in the substantia nigra pars compacta. Although the pathogenesis of PD is still unknown, the research findings from scientists are conducive to understand the pathological mechanisms. It is well accepted that both genetic and environmental factors contribute to the onset of PD. In this review, we summarize the mutations of main seven genes (α-synuclein, LRRK2, PINK1, Parkin, DJ-1, VPS35 and GBA1) linked to PD, discuss the potential mechanisms for the loss of dopaminergic neurons (dopamine metabolism, mitochondrial dysfunction, endoplasmic reticulum stress, impaired autophagy, and deregulation of immunity) in PD, and expect the development direction for treatment of PD.

Keywords: Parkinson disease; gene mutation; mechanism; neurodegeneration; neuronal death.

PubMed Disclaimer

References

    1. Ablat N., Lv D., Ren R., Xiaokaiti Y., Ma X., Zhao X., et al. (2016). Neuroprotective effects of a standardized flavonoid extract from safflower against a rotenone-induced rat model of Parkinson’s disease. Molecules 21:E1107. 10.3390/molecules21091107 - DOI - PMC - PubMed
    1. Akiyama H., McGeer P. L. (1989). Microglial response to 6-hydroxydopamine-induced substantia nigra lesions. Brain Res. 489 247–253. 10.1016/0006-8993(89)90857-3 - DOI - PubMed
    1. Alarcon-Aris D., Recasens A., Galofre M., Carballo-Carbajal I., Zacchi N., Ruiz-Bronchal E., et al. (2017). Selective alpha-synuclein knockdown in monoamine neurons by intranasal oligonucleotide delivery: potential therapy for Parkinson’s disease. Mol. Ther. 26 550–567. 10.1016/j.ymthe.2017.11.015 - DOI - PMC - PubMed
    1. Ando M., Fiesel F. C., Hudec R., Caulfield T. R., Ogaki K., Gorka-Skoczylas P., et al. (2017). The PINK1 p.I368N mutation affects protein stability and ubiquitin kinase activity. Mol. Neurodegener. 12:32. 10.1186/s13024-017-0174-z - DOI - PMC - PubMed
    1. Bae E. J., Yang N. Y., Lee C., Lee H. J., Kim S., Sardi S. P., et al. (2015). Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and alpha-synuclein aggregation. Exp. Mol. Med. 47:e153. 10.1038/emm.2014.128 - DOI - PMC - PubMed

LinkOut - more resources